Arry stock price target
Get the latest %COMPANY_NAME% ARRY detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. - ARRY - Stock Price Today - Zacks ARRY is up 2.61% today, Search | Nasdaq Yes! I would like to receive Nasdaq communications related to Products, Industry News and Events. You can always change your preferences or unsubscribe and your contact information is covered by Benzinga | Stock Market Quotes, Business News, Financial ... Jan 01, 2010 · Array BioPharma Inc. (NASDAQ: ARRY) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and peers on ARRY stock price (quote) - Array BioPharma Inc.
Jan 13, 2017 · All nine analysts tracking the stock maintain the equivalent of a "strong buy" rating -- though today's climb has left the average 12-month price target of $10.13 sitting underfoot.
The 6-Figure Options Bet on Soaring Array Biopharma Inc (ARRY) Jan 13, 2017 · All nine analysts tracking the stock maintain the equivalent of a "strong buy" rating -- though today's climb has left the average 12-month price target of $10.13 sitting underfoot. Array BioPharma Analysts | Markets Insider Array BioPharma Analysts: This is the Analysts-site for the company Array BioPharma on Markets Insider APPS - Digital Turbine Inc Stock quote - CNNMoney.com Find real-time APPS - Digital Turbine Inc stock quotes, company profile, news and forecasts from CNN Business. APPS - Digital Turbine Inc Stock quote - CNNMoney.com Markets UroGen Pharma Ltd. (URGN) Stock Price, Quote, History ...
Array BioPharma (NASDAQ:ARRY) had its price objective raised by equities research analysts at Jefferies Group to $13.00 in a note issued to investors on Friday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Jefferies Group’s price objective would indicate a potential upside of 5.95% from the company’s previous close. Several other […]
The Last Price shown is the last trade price at the time the quote page was displayed, and will not update every 10 seconds (as the Last Price at the top of the Quote page does). The Last Price will update only when the page is refreshed. Pivot points are used to identify … Analysts Upgrade/Downgrade Activity of Array BioPharma Inc ... Array BioPharma Inc. (NASDAQ:ARRY) belonging to the Medical sector has declined -1.83% and closed its last trading session at $11.77. The company reported its EPS on 02/09/2017. Currently, the stock has a 1 Year Price Target of $12.5. The consensus recommendation, according to Zacks Investment research, is 1.44. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Cowen & Co. Believes Array Biopharma (NASDAQ: ARRY) Still ... May 05, 2019 · Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Array Biopharma (ARRY – Research Report) yesterday and set a price target of $25.The company’s shares closed on Friday at $23.17, close to its 52-week high of $25.05. According to TipRanks.com, Shibutani is a 3-star analyst with an average return of 2.7% and a 43.3% success rate. . Shibutani covers the Healthcare sector
Pfizer stock could see some gains as it makes progress on a coronavirus Last summer, the Dow Jones component acquired Array Biopharma for $11.4 billion. In the first quarter, analysts polled by Zacks Investment Research call for
4 Speculative Biotechs With Huge Analyst Targets – 24/7 ... May 09, 2015 · Array BioPharma Inc. (NASDAQ: ARRY) was reiterated as Outperform at Wells Fargo, and the price target range for a value was put at $9.50 to $10.50 … Array BioPharma, Inc. (ARRY) Stock Message Board ... Jul 11, 2019 · Array BioPharma, Inc. (ARRY) Add ARRY Price Alert Hide Sticky Hide Intro: Moderator: Search This Board: Last Post and includes clinical candidates that are designed to regulate therapeutically important target proteins. The company's principal products include ARRY-886, which is an MEK inhibitor for cancer, and is in randomized phase II TipRanks
Analysts Upgrade/Downgrade Activity of Array BioPharma Inc ...
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array BioPharma - ARRY - Stock Price & News | The Motley Fool
26 Feb 2019 Out of eight analysts covering the stock, only Goldman Sachs' Paul Choi holds a more cautious “Hold” rating on ARRY – the rest are all buys. “ ARRY Price Target and Analyst Ratings (Array Biopharma) Nov 06, 2019 · 9 Wall Street analysts have issued ratings and price targets for Array Biopharma in the last 12 months. Their average twelve-month price target is $39.14, suggesting that the stock has a possible downside of 18.20%. The high price target for ARRY is $48.00 and the low price target for ARRY is $25.00. ARRY Stock Price, Forecast & News (Array Biopharma) 9 brokerages have issued 12 month price targets for Array Biopharma's shares. Their forecasts range from $25.00 to $48.00. On average, they anticipate Array Biopharma's share price to reach $39.14 in the next twelve months. This suggests that the stock has a possible downside of 18.2%. View analysts' price targets for Array Biopharma. ARRAY BIOPHARMA INC : ARRY Stock Price | MarketScreener Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.